Abstract:Objective Prior observational studies have reported that levels of sex hormones constitute a risk factor for the fracture. The aim of this study was to ascertain whether there is a causal relationship between the levels of sex hormones and the risk of fracture through Mendelian randomization (MR). Methods Single‐nucleotide polymorphisms (SNPs) associated with two indicators of sex hormone levels, circulating sex hormone‐binding globulin (SHBG) and bioavailable testosterone levels, as exposures were selected from a large genome‐wide association study (GWAS) from UK Biobank. The summary statistics for 11 different types of fracture as outcomes from the FinnGen consortium. This study employed the two‐sample MR approach. For the main analysis, the inverse‐variance‐weighted (IVW) method was utilized. To assess the heterogeneity of MR results, the IVW method and MR–Egger method were utilized. To evaluate potential pleiotropy, MR–Egger regression was conducted. Additionally, a leave‐one‐SNP‐out test was performed to assess the robustness of MR results to the exclusion of any individual SNP. Results The MR analyses demonstrated a conspicuous impact of SHBG on the risk of pathological fracture with osteoporosis (OP). We found that an increase of one standard deviation (SD) in SHBG correspondingly increased the risk of pathological fracture with OP [odds ratio (OR) 2.42, 95% confidence interval (CI), 1.52–3.85; p = 1.93 × 10−4]. The bioavailable testosterone showed the negative casual genetic associations with fractures of foot and forearm. An increase of one SD in the genetically predetermined bioavailable testosterone was associated with a reduction of 37% in the risk of fracture of foot (OR 0.63, 95% Cl 0.49 to 0.81; p = 3.37 × 10−4), as well as a 39% decrease in the risk of fracture of forearm (OR 0.61, 95% Cl 0.50 to 0.76; p = 5.40 × 10−6). Conclusions Our study confirms that individuals experiencing elevated SHBG concentrations showed a major causal effect on pathological fracture with OP. High bioavailable testosterone levels play an important role in preventing the fractures of foot and forearm. Although increasing bioavailable testosterone and decreasing SHBG levels had no casual effect on most fractures in the general population, they are likely to have the most clinically relevant effect on certain fracture risk reduction.

Evaluation of the Effect of Sodium‐Glucose Cotransporter 2 Inhibition on Fracture Risk: Evidence from Mendelian Randomization and Genetic Association Study

Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.

Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

HemoglobinA1c is a Risk Factor for Changes of Bone Mineral Density: A Mendelian Randomization Study

Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study

Genetically Predicted Sex Hormone-Binding Globulin and Bone Mineral Density: A Mendelian Randomization Study

Impact of SGLT2 inhibitors on lower limb complications: a mendelian randomization perspective

The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study

Association of Antihypertensive Drugs with Fracture and Bone Mineral Density: A Comprehensive Drug-Target Mendelian Randomization Study

Assessment of the effect of the SLC5A2 gene on eGFR: a Mendelian randomization study of drug targets for the nephroprotective effect of sodium-glucose cotransporter protein 2 inhibition

SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study

The Causal Impact of Childhood Obesity on Bone Mineral Density and Fracture in Adulthood: A Two-Sample Mendelian Randomization Study

Assessing the Casual Association Between Sex Hormone Levels and Fracture Risk: A Two‐Sample Mendelian Randomization Study

Effects of inhibitors of sodium-glucose cotransporter 2 on the skeleton of T2DM patients

Long-Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice

Fracture risks associated with sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: a population-based study in Hong Kong

Diabetes and osteoporosis: a two-sample mendelian randomization study

Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study

The Effect of Plasma Lipids and Lipid‐Lowering Interventions on Bone Mineral Density: A Mendelian Randomization Study

Association of sodium-glucose cotransporter 2 inhibitor use with risk of osteoporotic fracture among older women: A nationwide, population-based cohort study

The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization Study